Peptilotbeta

Latest research

The peptide literature, summarized and graded.

Every paper distilled to a plain-language summary with an honest evidence grade — from strong human trials to animal-only signals. 15 papers indexed and counting.

Ask the literature →
Sourceallpaperstrialsyoutube
Evidenceallreviewinsufficientlimited humananimal onlymoderate humanin vitro onlystrong humanpreclinical mixed
CompoundGLP-1semaglutidetirzepatideretatrutidethymosin beta-4BPC-157TB-500cagrilintidesermorelinsurvodutideGHK-CumazdutidePT-141melanotan
Filtered by #retatrutide · clear
🧪 TrialInsufficient

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Registered Phase 2 interventional trial (recruiting). Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

#retatrutide
ClinicalTrials.gov · Mar 2026View trial ↗
🧪 TrialInsufficient

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Registered Phase 3 interventional trial (recruiting). The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll abo

#tirzepatide#retatrutide
ClinicalTrials.gov · Sep 2025View trial ↗
🧪 TrialInsufficient

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Registered Phase 3 interventional trial (active not recruiting). This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

#retatrutide
ClinicalTrials.gov · Mar 2025View trial ↗
🧪 TrialInsufficient

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Registered Phase 3 interventional trial (active not recruiting). The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

#retatrutide
ClinicalTrials.gov · Apr 2024View trial ↗
🧪 TrialInsufficient

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Registered Phase 3 interventional trial (completed). The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

#retatrutide
ClinicalTrials.gov · Apr 2024View trial ↗
🧪 TrialInsufficient

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Registered Phase 3 interventional trial (active not recruiting). The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

#semaglutide#retatrutide
ClinicalTrials.gov · Feb 2024View trial ↗
🧪 TrialInsufficient

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Registered Phase 3 interventional trial (active not recruiting). The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

#retatrutide
ClinicalTrials.gov · Jul 2023View trial ↗
🧪 TrialInsufficient

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Registered Phase 3 interventional trial (completed). The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

#retatrutide
ClinicalTrials.gov · Jul 2023View trial ↗